ARS Pharmaceuticals (SPRY) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Product innovation and market positioning

• neffy is the first and only FDA and EMA/EC-approved needle-free epinephrine nasal spray for Type I allergic reactions, offering a compact, easy-to-carry alternative to autoinjectors and launched in Q4 2024 with strong initial uptake.

• The product leverages patented absorption technology and strong IP protection, blocking competitors from nasal epinephrine products below four milligrams and extending protection to at least 2039.

• neffy is positioned to address significant unmet needs, especially among patients reluctant to use or carry autoinjectors, and is modeled after successful nasal emergency products like Narcan.

• The device is highly reliable, stable at high temperatures (5°F–122°F), and removes injection-related warnings, aligning with new treatment guidelines.

• Initial commercialization targets patients who refuse or are reluctant to use autoinjectors, with rapid expansion planned to broader demographics and strong engagement from HCPs.

Commercial performance and growth strategy

• neffy launched in late September, achieving $7.1 million in first-quarter sales, outperforming both internal and analyst forecasts.

• Over 50% of high-decile doctors have prescribed neffy, with >3,000 HCPs prescribing and >200 new HCPs added weekly; 1,750+ HCPs enrolled in the neffy Experience Program.

• Insurance coverage is expanding rapidly, with 60% coverage expected by end of Q1, over 80% by end of Q3 2025, and Express Scripts adding neffy to its formulary as tier two preferred.

• The company maintains a strong cash position with over $300 million and no debt, supporting aggressive marketing, DTC campaigns, and sales force expansion to 200+ reps by 2026.

• Marketing activity expansion is not expected to impact the company’s guidance of at least three years of operating runway based on cash on hand.

Market opportunity and expansion

• The current prescription epinephrine market is valued at $3 billion, with a potential $7 billion expansion by reaching untreated populations and new indications.

• neffy aims to convert over 80% of current autoinjector users and recapture those who previously refused prescriptions, with HCP survey data indicating it could become the treatment of choice for 60% of target prescribers within 12 months and 92% within 24 months.

• Global commercialization is underway, with approvals in the US and Europe, filings in Japan, China, Australia, UK, and Canada, and strategic partnerships for worldwide distribution, securing $570 million in milestones and royalties.

• Projected $425 million annual peak sales in the ALK region (excluding US, China, Japan, AUS/NZ).

• The product is expected to become the preferred choice among prescribers as comfort and experience grow.